Hybio Pharmaceutical (300199.SZ) Earnings Analysis
Hybio Pharmaceutical (300199.SZ) has no confirmed upcoming earnings date. Trailing P/E 201.15.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300199.SZ next report earnings?
No confirmed upcoming earnings date is currently scheduled for 300199.SZ. This page updates as the calendar is published.
300199.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-10-30 | -0.08391 CNY | n/a | n/a | n/a |
| 2025-04-25 | 0.08 CNY | n/a | n/a | n/a |
| 2024-08-23 | 0.00424 CNY | n/a | n/a | n/a |
300199.SZ valuation and analyst view
| Trailing P/E | 201.15 |
|---|---|
| Trailing EPS | 0.10353 CNY |
| Price / book | 25.90 |
| Dividend yield | 0.00% |
| Market cap | 18.96B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Hybio Pharmaceutical (300199.SZ)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 300199.SZ. This page updates as the calendar is published.
Did 300199.SZ beat earnings last quarter?
Consensus estimate data was not available for 300199.SZ's 2025-10-30 report.
What is 300199.SZ's current P/E ratio and EPS?
300199.SZ trades at a trailing P/E of 201.15 on trailing EPS of 0.10352681280867516 CNY.
What do analysts rate 300199.SZ?
300199.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.